
FibroBiologics · Patent-Pending Research
We have filed a patent application for engineered cells designed to produce GLP-1 and other peptides continuously, from inside the body.
01 — The Basics
GLP-1 is a natural hormone your gut releases after you eat.
It helps control blood sugar, slows digestion, and signals fullness to the brain. Since natural GLP-1 breaks down within minutes, today’s GLP-1 medications, widely used for type 2 diabetes and weight management, are chemically modified to last longer and provide sustained effects.

Current GLP-1 medicines generally require weekly injections or daily pills, and the benefits of GLP-1 therapy are lost once the treatment is stopped.
Weekly injections or daily pills, often for the long term.
Levels can rise after each dose and fall before the next, rather than staying steady.
Worldwide demand for GLP-1 medicines has been constrained by manufacturing bottlenecks.
02 — Our Approach
Instead of making a peptide outside the body and relying on repeat dosing, our approach harnesses engineered living cells to provide a sustained internal source of therapeutic peptides such as GLP-1.
The patent application describes specialized three-dimensional structures composed of cells engineered to produce GLP-1. Once administered, they are designed to continuously produce GLP-1, which could potentially reduce the need for frequent dosing.

Fibroblasts or other cells are engineered to produce and secrete a selected therapeutic peptide, such as GLP-1.

03 — More than GLP-1
The patent application extends beyond weight management or diabetes.
It covers GLP-1, GIP and GLP-2 class peptides, and the technology could be adapted to produce many other therapeutic proteins and peptides. The technology also enables the production of more than one peptide at a time, in ratios tailored to the patient or condition.
GLP-1
GIP
GLP-2
Metabolic & diabetes
Gastrointestinal
Autoimmune & inflammatory
Wound healing
Hormone deficiencies
Cancer
Age-related conditions
The application also describes safety switches designed to allow the cells to be selectively eliminated if needed, retrievable devices to contain them, and modifications intended to support potential off-the-shelf use.

The Bigger Picture
Pete O’Heeron · Founder & CEO
This technology is investigational and the subject of a pending patent application. It has not been evaluated by the FDA or any other regulatory authority.
04 — FAQ
What is FibroBiologics’ GLP-1 technology?
A cell-based platform designed to use engineered cells to continuously produce and release physiological concentrations of GLP-1 and other therapeutic peptides inside the body. This technology is described in a U.S. patent application filed by FibroBiologics in October 2026.
Is this available to patients?
No. The technology is investigational and the subject of a pending patent application. It has not been evaluated or approved by the FDA or any other regulatory authority.
How is it different from GLP-1 injections or pills?
Current GLP-1 medicines are manufactured outside the body and typically administered as weekly injections or daily pills. In contrast, engineered cells are designed to continuously produce and release the peptide within the body, following a single administration.
What are spheroids and organoids?
Small, three-dimensional clusters of cells that resemble the structure and function of human tissue.
Where can investors learn more?
Read the full press release, visit ir.fibrobiologics.com, or sign up for email alerts. FibroBiologics trades on Nasdaq under the ticker FBLG.
NASDAQ: FBLG
This page contains forward-looking statements. Actual results may differ materially. See the full cautionary statement in our press release and SEC filings.